Evidence map›Paper›PMID 25970613›Full record

ArticlePLoS neglected tropical diseases2015

Pathogenesis of progressive scarring trachoma in Ethiopia and Tanzania and its implications for disease control: two cohort studies.

Matthew J Burton, Saul N Rajak, Victor H Hu, Athumani Ramadhani, Esmael Habtamu, Patrick Massae, Zerihun Tadesse, Kelly Callahan, Paul M Emerson, Peng T Khaw and 5 more

Open access · goldAbstract read
In one paragraph

Article in PLoS neglected tropical diseases, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed, 1 pooled it
6.9field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

52 citing papers in PubMed, 1 synthesis or guideline pooled it, 70 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Trachoma.Lancet (London, England) · 2025
    Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Trachoma risk factors in Oromia Region, Ethiopia.PLoS neglected tropical diseases · 2023
    Article
  17. Modelling morbidity for neglected tropical diseases: the long and winding road from cumulative exposure to long-term pathology.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2023
    Review
  18. Article
  19. Trachoma.Nature reviews. Disease primers · 2022
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 9 institutions in 5 countries.

Matthew J BurtonFaculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London, United Kingdom; National Institute for Health Research (NIHR) Biomedical Research Centre at Moorfields Eye Hospital and University College London (UCL) Institute of Ophthalmology, London, United Kingdom; Department of Ophthalmology, Kilimanjaro Christian Medical Centre, Moshi, Tanzania.
Saul N RajakFaculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London, United Kingdom.
Victor H HuFaculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London, United Kingdom; Department of Ophthalmology, Kilimanjaro Christian Medical Centre, Moshi, Tanzania.
Athumani RamadhaniFaculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London, United Kingdom; Department of Ophthalmology, Kilimanjaro Christian Medical Centre, Moshi, Tanzania.
Esmael HabtamuFaculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London, United Kingdom; The Carter Center, Addis Ababa, Ethiopia.
Patrick MassaeDepartment of Ophthalmology, Kilimanjaro Christian Medical Centre, Moshi, Tanzania.
Zerihun TadesseThe Carter Center, Addis Ababa, Ethiopia.
Kelly CallahanThe Carter Center, Atlanta, Georgia, United States of America.
Paul M EmersonInternational Trachoma Initiative, Atlanta, Georgia, United States of America.
Peng T KhawNational Institute for Health Research (NIHR) Biomedical Research Centre at Moorfields Eye Hospital and University College London (UCL) Institute of Ophthalmology, London, United Kingdom.
David JeffriesMedical Research Council (MRC) Laboratories, Fajara, The Gambia.
David C W MabeyFaculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London, United Kingdom.
Robin L BaileyFaculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London, United Kingdom.
Helen A WeissMedical Research Council (MRC) Tropical Epidemiology Group, London School of Hygiene & Tropical Medicine, London, United Kingdom.
Martin J HollandFaculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London, United Kingdom.
London School of Hygiene & Tropical Medicine · GBKilimanjaro Christian Medical Centre · TZThe Carter Center · ETCarter Center · USInternational Trachoma Initiative · USMedical Research Council · GBMoorfields Eye Hospital · GBMRC Unit the Gambia · GMUniversity College London · GB

Funding

Medical Research Council MR/K012126/1Wellcome Trust 080741/Z/06/ZWellcome Trust 098481/Z/12/ZWellcome Trust 100714Wellcome Trust 98481
6 · The paper itself

Abstract

backgroundTrachoma causes blindness through a conjunctival scarring process initiated by ocular Chlamydia trachomatis infection; however, the rates, drivers and pathophysiological determinants are poorly understood. We investigated progressive scarring and its relationship to conjunctival infection, inflammation and transcript levels of cytokines and fibrogenic factors. METHODOLOGY/PRINCIPAL

findingsWe recruited two cohorts, one each in Ethiopia and Tanzania, of individuals with established trachomatous conjunctival scarring. They were followed six-monthly for two years, with clinical examinations and conjunctival swab sample collection. Progressive scarring cases were identified by comparing baseline and two-year photographs, and compared to individuals without progression. Samples were tested for C. trachomatis by PCR and transcript levels of S100A7, IL1B, IL13, IL17A, CXCL5, CTGF, SPARCL1, CEACAM5, MMP7, MMP9 and CD83 were estimated by quantitative RT-PCR. Progressive scarring was found in 135/585 (23.1%) of Ethiopian participants and 173/577 (30.0%) of Tanzanian participants. There was a strong relationship between progressive scarring and increasing inflammatory episodes (Ethiopia: OR 5.93, 95%CI 3.31-10.6, p<0.0001. Tanzania: OR 5.76, 95%CI 2.60-12.7, p<0.0001). No episodes of C. trachomatis infection were detected in the Ethiopian cohort and only 5 episodes in the Tanzanian cohort. Clinical inflammation, but not scarring progression, was associated with increased expression of S100A7, IL1B, IL17A, CXCL5, CTGF, CEACAM5, MMP7, CD83 and reduced SPARCL1. CONCLUSIONS/SIGNIFICANCE: Scarring progressed in the absence of detectable C. trachomatis, which raises uncertainty about the primary drivers of late-stage trachoma. Chronic conjunctival inflammation appears to be central and is associated with enriched expression of pro-inflammatory factors and altered expression of extracellular matrix regulators. Host determinants of scarring progression appear more complex and subtle than the features of inflammation. Overall this indicates a potential role for anti-inflammatory interventions to interrupt progression and the need for trichiasis disease surveillance and surgery long after chlamydial infection has been controlled at community level.

Indexed as

AdultBlindnessCarcinoembryonic AntigenChlamydia trachomatisCicatrixCohort StudiesConjunctivaConnective Tissue Growth FactorCytokinesDisease ProgressionEthiopiaFemaleGPI-Linked ProteinsHumansInflammationInterleukin-17Carcinoembryonic AntigenCCN2 protein, humanCEACAM5 protein, humanConnective Tissue Growth FactorCytokinesGPI-Linked ProteinsIL17A protein, humanInterleukin-17Matrix Metalloproteinase 7MMP7 protein, humanS100A7 protein, humanS100 Calcium Binding Protein A7S100 Proteins

Identifiers

PMID25970613
PMCPMC4430253
OpenAlexW324911061

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.